|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: XPNPEP2 |
Gene summary for XPNPEP2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | XPNPEP2 | Gene ID | 7512 |
| Gene name | X-prolyl aminopeptidase 2 | |
| Gene Alias | AEACEI | |
| Cytomap | Xq26.1 | |
| Gene Type | protein-coding | GO ID | GO:0006508 | UniProtAcc | O43895 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 7512 | XPNPEP2 | HCC1_Meng | Human | Liver | HCC | 1.81e-21 | 4.94e-02 | 0.0246 |
| 7512 | XPNPEP2 | HCC1 | Human | Liver | HCC | 1.16e-43 | 4.36e+00 | 0.5336 |
| 7512 | XPNPEP2 | HCC2 | Human | Liver | HCC | 9.63e-39 | 3.85e+00 | 0.5341 |
| 7512 | XPNPEP2 | S014 | Human | Liver | HCC | 9.71e-19 | 6.41e-01 | 0.2254 |
| 7512 | XPNPEP2 | S015 | Human | Liver | HCC | 1.68e-19 | 9.95e-01 | 0.2375 |
| 7512 | XPNPEP2 | S016 | Human | Liver | HCC | 1.58e-33 | 1.08e+00 | 0.2243 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| XPNPEP2 | SNV | Missense_Mutation | c.1073A>G | p.Asn358Ser | p.N358S | O43895 | protein_coding | deleterious(0.04) | benign(0.104) | TCGA-BH-A0H0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| XPNPEP2 | SNV | Missense_Mutation | c.1255N>C | p.Ile419Leu | p.I419L | O43895 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-EW-A1PB-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| XPNPEP2 | insertion | Frame_Shift_Ins | novel | c.965_966insTTATTATA | p.Trp323TyrfsTer17 | p.W323Yfs*17 | O43895 | protein_coding | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD | ||
| XPNPEP2 | insertion | Frame_Shift_Ins | novel | c.967_968insCCATCCCCATTTTACAAATGTGCAAAATGGAACACAGA | p.Trp323SerfsTer27 | p.W323Sfs*27 | O43895 | protein_coding | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD | ||
| XPNPEP2 | deletion | Frame_Shift_Del | novel | c.1563delG | p.Thr522GlnfsTer54 | p.T522Qfs*54 | O43895 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| XPNPEP2 | SNV | Missense_Mutation | c.1974N>C | p.Trp658Cys | p.W658C | O43895 | protein_coding | tolerated_low_confidence(0.12) | benign(0.174) | TCGA-EK-A2RO-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| XPNPEP2 | SNV | Missense_Mutation | novel | c.783C>A | p.Phe261Leu | p.F261L | O43895 | protein_coding | tolerated(0.14) | possibly_damaging(0.472) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| XPNPEP2 | SNV | Missense_Mutation | c.747N>G | p.Phe249Leu | p.F249L | O43895 | protein_coding | tolerated(0.19) | possibly_damaging(0.849) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| XPNPEP2 | SNV | Missense_Mutation | novel | c.1306N>A | p.Glu436Lys | p.E436K | O43895 | protein_coding | deleterious(0.02) | possibly_damaging(0.859) | TCGA-JX-A3Q0-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
| XPNPEP2 | SNV | Missense_Mutation | c.68N>A | p.Thr23Lys | p.T23K | O43895 | protein_coding | deleterious_low_confidence(0.01) | benign(0.006) | TCGA-LP-A7HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 7512 | XPNPEP2 | DRUGGABLE GENOME, PROTEASE, ENZYME | inhibitor | CHEMBL2103847 | TOSEDOSTAT | |
| 7512 | XPNPEP2 | DRUGGABLE GENOME, PROTEASE, ENZYME | inhibitor | 252827461 | ||
| 7512 | XPNPEP2 | DRUGGABLE GENOME, PROTEASE, ENZYME | inhibitor | 252166832 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |